{"entity":{"id":"luveltamab-tazevibulin","kind":"drug","name":"Luveltamab tazevibulin","aka":[],"tldr":"A folate-receptor ADC designed to work across low and high receptor levels, in a pivotal ovarian cancer trial.","summary":"Sutro Biopharma's site-specifically conjugated FRα ADC. Phase 1 showed responses in FRα-low as well as FRα-high tumours; the phase 2/3 REFRαME-O1 trial in platinum-resistant ovarian cancer (any FRα expression >25%) is ongoing, with an interim analysis expected in 2026. Neutropenia and arthralgia are characteristic.","status":"phase-3","asOf":"2026-09-07","links":[{"label":"REFRαME-O1","url":"https://clinicaltrials.gov/study/NCT05870748"}],"tags":[],"related":[],"cancers":["ovarian","endometrial"],"sections":[],"technologies":["adc","site-specific-conjugation"],"targets":["folr1"],"drugs":[],"companies":["sutro-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05870748"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"code":"STRO-002","modality":"ADC","payload":"SC209 (hemiasterlin, tubulin inhibitor), DAR ~4","linker":"Cleavable, site-specific (Sutro XpressCF)","mechanism":"Anti-FRα antibody with a hemiasterlin microtubule inhibitor conjugated at defined non-natural amino acids.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/luveltamab-tazevibulin/","neighbours":{"cancer":[{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/"}],"target":[{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/"}],"company":[{"id":"sutro-biopharma","kind":"company","name":"Sutro Biopharma","route":"/companies/sutro-biopharma/"}],"trial":[{"id":"nct05870748","kind":"trial","name":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","route":"/trials/nct05870748/"}],"idea":[{"id":"idea-fra-adc-sequencing-ovarian","kind":"idea","name":"Sequence folate-receptor ADCs by payload class","route":"/ideas/idea-fra-adc-sequencing-ovarian/"}]}}